bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure S8 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Gating strategy used to determine PR1-CTL frequency in peripheral blood of multiple myeloma patients following autologous stem cell transplantation
Supplemental Figure S7 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Phenotype of PR1-CTL in patients following allo-SCT
Supplementary Results, Supplementary Figure 1 from Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
Authors: Kalli Kimberly R. , Block Matthew S. , Kasi Pashtoon M. , Erskine Courtney L. , Hobday Timothy J. , Dietz Allan , Padley Douglas , Gustafson Michael P. , Shreeder Barath , Puglisi-Knutson Danell , Visscher Dan W. , Mangskau Toni K. , Wilson Glynn , Knutson Keith L.
Published: April 2023

Figure S1: Vaccination generates T cell immunity to FR following immunization.
Supplemental Figure S4 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

HLA-A2 expression on U266 after addition of inhibitors
Supplemental Figure S2 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

NE and P3 localize within the cell following co-culture with U266 MM cells
Supplemental Figure S1 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Transcript expression of NE and P3 genes in CCLE
Supplementary Figure 6 from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

KEAP1 and NFR2 target genes analyses
Supplementary Figure 3 from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

Gene expression analysis of other lung cancer datasets and prognostic signatures
Supplementary Figure 2 from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

Additional analyses on IEO and TCGA cohorts
Supplementary Figure legends from Expression and Therapeutic Potential of SOX9 in Chordoma
Authors: Chen Hua , Garbutt Cassandra C. , Spentzos Dimitrios , Choy Edwin , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

Supplementary Figure legends
Table S5 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

GAUSS GA101 CFHR3 Protein and FLIPI
Supplementary Table 2. from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Authors: Ibrahimpasic Tihana , Xu Bin , Landa Iñigo , Dogan Snjezana , Middha Sumit , Seshan Venkatraman , Deraje Shyam , Carlson Diane L. , Migliacci Jocelyn , Knauf Jeffrey A. , Untch Brian , Berger Michael F. , Morris Luc , Tuttle R. Michael , Chan Timothy , Fagin James A. , Ghossein Ronald , Ganly Ian
Published: April 2023

All IMPACT mutation calls. Tumors previously published by Landa et al (1) are highlighted in blue.
Frigure S3 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

Serum protein expression levels by best overall response
Figure S2 from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Authors: Ibrahimpasic Tihana , Xu Bin , Landa Iñigo , Dogan Snjezana , Middha Sumit , Seshan Venkatraman , Deraje Shyam , Carlson Diane L. , Migliacci Jocelyn , Knauf Jeffrey A. , Untch Brian , Berger Michael F. , Morris Luc , Tuttle R. Michael , Chan Timothy , Fagin James A. , Ghossein Ronald , Ganly Ian
Published: April 2023

Mutations in DNA damage control (A), RAS/PI3K/AkT/MTOR pathways (B), chromatin modifying genes (C) and receptor tyrosine kinase genes (RTKs) (D) in fatal non-anaplastic thyroid cancer.
Figure S1 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

Serum protein expression levels by genotype
Supplementary material from Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer
Authors: Kroeger David R. , Milne Katy , Nelson Brad H.
Published: April 2023

Supplementary methods. Table S1. PC-derived immunoglobulin heavy (IGH) V, D, and J region usage and consensus junction amino acid sequences for distinct VDJ families as determined by Sanger sequencing and IMGT V-QUEST alignment Table S2. Genes with greater than 10-fold differential expression between tumors with high numbers of PC ("PC", n=4) versus no B-lineage cells ("no PC/B cells" n=3), or high numbers of PC versus tumors with CD20+ TIL but without PCs ("B cells", n=2) (based on average transcript counts in NanoString analysis of FFPE tumor tissue). Table S3. Differentiation, overexpressed, and CT antigen genes analyzed for expression in TCGA microarray data. Table S4. List of genes that by hierarchical clustering were differentially expressed in tumors with a PC signature (Fig. S3). Table S5. Clinical characteristics of HGSC patients represented on the 172-case TMA used for survival analysis; P-values refer to results of univariate analyses between the indicated variable and disease-specific survival using one-way ANOVA or chi-squared tests. Table S6. Antibodies used in this study. Fig. S1. Immunoglobulin heavy chain expression in HGSC. Standardized read count (FPKM) data for 9 immunoglobulin heavy chain classes were plotted using TCGA HGSC RNA-seq data. Fig. S2. Lack of association between the PC gene signature and immunogenic mutations, TP53 mutations, and differentiation/overexpressed antigens in HGSC. Fig. S3. Heatmap of CT antigen expression.
Supplementary Material from miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5
Authors: Stiegelbauer Verena , Vychytilova-Faltejskova Petra , Karbiener Michael , Pehserl Anna-Maria , Reicher Andreas , Resel Margit , Heitzer Ellen , Ivan Cristina , Bullock Marc , Ling Hui , Deutsch Alexander , Wulf-Goldenberg Annika , Adiprasito Jan Basri , Stoeger Herbert , Haybaeck Johannes , Svoboda Marek , Stotz Michael , Hoefler Gerald , Slaby Ondrej , Calin George Adrian , Gerger Armin , Pichler Martin
Published: April 2023

Supplementary Material
Supplemental Figures from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Authors: Exley Mark A. , Friedlander Phillip , Alatrakchi Nadia , Vriend Lianne , Yue Simon , Sasada Tetsuro , Zeng Wanyong , Mizukami Yo , Clark Justice , Nemer David , LeClair Kenneth , Canning Christine , Daley Heather , Dranoff Glenn , Giobbie-Hurder Anita , Hodi F. Stephen , Ritz Jerome , Balk Steven P.
Published: April 2023

Supplemental Figures
Supplementary Table 3 from A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Seymour Erlene , Saiya-Cork Kamlai , Parkin Brian , Shedden Kerby , Malek Sami N.
Published: April 2023

Details of recurrent gene mutations per case, deep panel based VAFs, ddPCR results, author's annotations, SNP 6.0 arrays based aCNA profiling.
Supplemental Tables 1, 3, and 6; Supplemental Figures 1-5 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Authors: Liu Joyce F. , Palakurthi Sangeetha , Zeng Qing , Zhou Shan , Ivanova Elena , Huang Wei , Zervantonakis Ioannis K. , Selfors Laura M. , Shen Yiping , Pritchard Colin C. , Zheng Mei , Adleff Vilmos , Papp Eniko , Piao Huiying , Novak Marian , Fotheringham Susan , Wulf Gerburg M. , English Jessie , Kirschmeier Paul T. , Velculescu Victor E. , Paweletz Cloud , Mills Gordon B. , Livingston David M. , Brugge Joan S. , Matulonis Ursula A. , Drapkin Ronny
Published: April 2023

Table S1: Optimal conditions for PDX luciferization; Table S3: BROCA characterization; Table S6: PIK3CA FISH. Figure S1: Schema for PDX generation; Figures S2: IHC of DF68; Figure S3: Array CGH of DF86; Figure S4: PI3K pathway analysis from RPPA; Figure S5: Correlation between BLI and plasma CA125
Supplemental Table 5 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Authors: Liu Joyce F. , Palakurthi Sangeetha , Zeng Qing , Zhou Shan , Ivanova Elena , Huang Wei , Zervantonakis Ioannis K. , Selfors Laura M. , Shen Yiping , Pritchard Colin C. , Zheng Mei , Adleff Vilmos , Papp Eniko , Piao Huiying , Novak Marian , Fotheringham Susan , Wulf Gerburg M. , English Jessie , Kirschmeier Paul T. , Velculescu Victor E. , Paweletz Cloud , Mills Gordon B. , Livingston David M. , Brugge Joan S. , Matulonis Ursula A. , Drapkin Ronny
Published: April 2023

Table S5: Somatic Sequence Alterations in parental tumor and xenograft DF149
Supplemental Table 2 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Authors: Liu Joyce F. , Palakurthi Sangeetha , Zeng Qing , Zhou Shan , Ivanova Elena , Huang Wei , Zervantonakis Ioannis K. , Selfors Laura M. , Shen Yiping , Pritchard Colin C. , Zheng Mei , Adleff Vilmos , Papp Eniko , Piao Huiying , Novak Marian , Fotheringham Susan , Wulf Gerburg M. , English Jessie , Kirschmeier Paul T. , Velculescu Victor E. , Paweletz Cloud , Mills Gordon B. , Livingston David M. , Brugge Joan S. , Matulonis Ursula A. , Drapkin Ronny
Published: April 2023

Table S2: Array CGH characterization of PDX models
supplemental figure legend from Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Ashizawa Tadashi , Iizuka Akira , Nonomura Chizu , Kondou Ryota , Maeda Chie , Miyata Haruo , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Katano Ikumi , Ito Mamoru , Akiyama Yasuto
Published: April 2023

supplemental figure legend
Supplementary Table 2 from Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Ashizawa Tadashi , Iizuka Akira , Nonomura Chizu , Kondou Ryota , Maeda Chie , Miyata Haruo , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Katano Ikumi , Ito Mamoru , Akiyama Yasuto
Published: April 2023

Engraftment of human PBMCs in humanized NOG-dKO mice treated with anti-PD-1 antibody.
Table S3 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

Cytotoxicity of different NKG2D-CAR redirected T cell subpopulations against osteosarcoma cells.
Supplementary Figure 4 from Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Ashizawa Tadashi , Iizuka Akira , Nonomura Chizu , Kondou Ryota , Maeda Chie , Miyata Haruo , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Katano Ikumi , Ito Mamoru , Akiyama Yasuto
Published: April 2023

Effect od anti-PD-1 antibody on SCC3 and U87 tumor growth in vivo.
Table S1 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

List of fluorochrome labeled monoclonal antibodies used for flow cytometry analysis.
Supplementary Figures 1-5 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Supplementary Figure 1: Clinical status of patients included in the analysis Supplementary Figure 2: Unadjusted Kaplan Meier survival curves of patients who received ACEi (green), ARB (yellow) vs. control group (blue). Supplementary Figure 3: Chronic ASI use in resected patients with hypertension. Supplementary Figure 4: Unadjusted Kaplan Meier survival curve of all resected patients stratified by BMI and chemotherapy. Supplementary Figure 5: Unadjusted Kaplan Meier curves for disease recurrence.
Supplementary Table 2 from T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy
Authors: Wang Tianjiao , Lu Ye , Polk Avery , Chowdhury Pinki , Zamalloa Carlos Murga , Fujiwara Hiroshi , Suemori Koichiro , Beyersdorf Niklas , Hristov Alexandra C. , Lim Megan S. , Bailey Nathanael G. , Wilcox Ryan A.
Published: April 2023

Supplementary Table 2 plasmids shRNA
Supplementary Table 1 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Authors: Liu Geoffrey , Cuffe Sinead , Liang Shermi , Azad Abul Kalam , Cheng Lu , Brhane Yonathan , Qiu Xin , Cescon David W. , Bruce Jeffrey , Chen Zhuo , Cheng Dangxiao , Patel Devalben , Tse Brandon C. , Laurie Scott A. , Goss Glenwood , Leighl Natasha B. , Hung Rayjean , Bradbury Penelope A. , Seymour Lesley , Shepherd Frances A. , Tsao Ming Sound , Chen Bingshu E. , Xu Wei , Reisman David N.
Published: April 2023

Comparison of Analyzed and Non-Analyzed Data from the PM Cohort. This table was an analysis requested by a reviewer.
Supplemental Tables 1-7 and Supplemental Figure 1 from RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Authors: Kato Shumei , Subbiah Vivek , Marchlik Erica , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1. Selected ongoing clinical trials targeting RET aberrations; Supplemental Table 2. Cancer diagnosis that were negative for RET aberration (included cases with N {greater than or equal to}10); Supplemental Table 3. Complete list of RET aberration with cancer diagnosis and co-occurring aberrations; Supplemental Table 4. List of 182 and 236 cancer-related genes; Supplemental Table 4.B. List of 236 cancer-related genes (N=72); Supplemental Table 5. RET aberrations reported in cBioPortal database; Supplemental Table 6. Co-aberrant oncogenic pathways and the type of RET aberrations; Supplemental Table 7. Co-occurring aberrations associated with RET aberrations and examples of possible targeted therapies; Supplemental Figure 1. Comparison of RET aberrations between current report and cBioPortal.
Supplemental Figure 3 from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Authors: LaCerte Carl , Ivaturi Vijay , Gobburu Joga , Greer Jacqueline M. , Doyle L. Austin , Wright John J. , Karp Judith E. , Rudek Michelle A.
Published: April 2023

Conditional Weighted Residuals versus Time or Predicted Concentration: Total Flavopiridol (A and C), Unbound Flavopiridol (B and D).
Supplementary Figure 3 from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
Authors: Sinnott Jennifer A. , Peisch Sam F. , Tyekucheva Svitlana , Gerke Travis , Lis Rosina , Rider Jennifer R. , Fiorentino Michelangelo , Stampfer Meir J. , Mucci Lorelei A. , Loda Massimo , Penney Kathryn L.
Published: April 2023

Supplementary Figure 3. Violin plots displaying the distributions of the signature predictions among 4 categories of Gleason score 7: core grade 3 with non-lethal outcome, core grade 3 with lethal outcome, core grade 4 with non-lethal outcome, core grade 4 with lethal outcome, which are similar to those in the main analysis.
Supplementary Figure 2 from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
Authors: Sinnott Jennifer A. , Peisch Sam F. , Tyekucheva Svitlana , Gerke Travis , Lis Rosina , Rider Jennifer R. , Fiorentino Michelangelo , Stampfer Meir J. , Mucci Lorelei A. , Loda Massimo , Penney Kathryn L.
Published: April 2023

Supplementary Figure 2. Receiver Operating Characteristic (ROC) curve for the Gleason signature (from Penney et al.), applied to the new expression data for the men in the HPFS with Gleason {less than or equal to}6 and Gleason {greater than or equal to}8 to predict high vs low Gleason score.
Supplementary Table from Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Authors: Sagawa Morihiko , Ohguchi Hiroto , Harada Takeshi , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Kizaki Masahiro , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

Primers for quantitative real-time polymerase chain reaction (QRT-PCR)
Supplemental Figure 2 from Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Authors: Khagi Yulian , Goodman Aaron M. , Daniels Gregory A. , Patel Sandip P. , Sacco Assuntina G. , Randall James M. , Bazhenova Lyudmila A. , Kurzrock Razelle
Published: April 2023

S. Figure 2 Landmark PFS Total Alterations
Supplementary Figure 1 from Administration of Non-Torsadogenic human Ether-à-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG–Expressing Glioblastoma Patients
Authors: Pointer Kelli B. , Clark Paul A. , Eliceiri Kevin W. , Salamat M. Shahriar , Robertson Gail A. , Kuo John S.
Published: April 2023

The number of patients who received each combination of hERG blockers is shown.
Overall survival estimates (landmark survival analysis) from Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Authors: Champiat Stéphane , Dercle Laurent , Ammari Samy , Massard Christophe , Hollebecque Antoine , Postel-Vinay Sophie , Chaput Nathalie , Eggermont Alexander , Marabelle Aurélien , Soria Jean-Charles , Ferté Charles
Published: April 2023

*HPD adapted RECIST classes: complete response (CR), partial response (PR) and stable disease (SD) remained as defined by RECIST 1.1. Regarding progressive disease patients, these were allocated to PD non-HPD and to HPD. HPD patients are defined as progressive disease (PD) by RECIST 1.1 at the first evaluation and an increase {greater than or equal to} two-fold in the TGR EXPERIMENTAL compared to REFERENCE period.
Multivariate linear regression model evaluating the association between tumor response (RECIST, %) and the following variables : age > 65 y.o. (yes/no), TGR REFERENCE and the Royal Marsden Prognostic from Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Authors: Champiat Stéphane , Dercle Laurent , Ammari Samy , Massard Christophe , Hollebecque Antoine , Postel-Vinay Sophie , Chaput Nathalie , Eggermont Alexander , Marabelle Aurélien , Soria Jean-Charles , Ferté Charles
Published: April 2023

* To be clinically meaningful, estimates are computed for 10% variation in TGR
Supplementary File from Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment
Authors: Niu Xiaomin , Liu Fatao , Zhou Yi , Zhou Zhen , Zhou Daizhan , Wang Ting , Li Ziming , Ye Xiangyun , Yu Yongfeng , Weng Xiaoling , Zhang Hong , Ye Junyi , Liao Meilin , Liu Yun , Chen Zhiwei , Lu Shun
Published: April 2023

Supplementary Methods and Figure legend of Supplementary Figure S1.
Supplementary Table S6 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Expression of the CD274 and other 9p24 or immune-related genes.
Supplementary Table S2 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Origin of SCLCs
Supplementary Methods + Figures from Therapeutic Inhibition of the MDM2–p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas
Authors: Nör Felipe , Warner Kristy A. , Zhang Zhaocheng , Acasigua Gerson A. , Pearson Alexander T. , Kerk Samuel A. , Helman Joseph I. , Sant'Ana Filho Manoel , Wang Shaomeng , Nör Jacques E.
Published: April 2023

Supplementary Materials and Methods: Immunohistochemistry, Immunofluorescence, TUNEL staining Supplementary Figure S1. Treatment with MI-773 and/or cisplatin is not toxic to mice. Graph depicting mouse weight during the experimental period. Data were normalized against pre-treatment weight. Supplementary Figure S2. Representative photomicrographs of UM-HACC-5 and -6 cells exposed to 1 μM MI-773 and/or 2 μM cisplatin, or vehicle control, for 72 hours in vitro. Supplementary Figure S3. Representative graphs depicting the number of UM-HACC-5 (A) and -6 (B) cells in each cell-cycle phase after treatment with 1 μM MI-773 and/or 2 μM cisplatin, or vehicle control, for 24 hours. Supplementary Figure S4. Representative photomicrographs obtained by immunofluorescence for ALDH (green) in UM-PDX-HACC-5 tumors treated with MI-773 and/or cisplatin. ALDH-positive cells are predominantly observed in vehicle and cisplatin groups (details) and are apparently located in close proximity to blood vessels (*) and nerve structures (N). Scale bar represents 50 μm (400x).
Supplementary Fig S1 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

SNP chip analysis of three tumors from cohort 1.
Dasatinib CRD from Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Authors: Spilker Mary E. , Chen Xiaoying , Visswanathan Ravi , Vage Chandra , Yamazaki Shinji , Li Gang , Lucas Judy , Bradshaw-Pierce Erica L. , Vicini Paolo
Published: April 2023

Dasatinib CRD Calculation Details
Supplementary Material S4 from How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software
Authors: Dugué Audrey Emmanuelle , Pulido Marina , Chabaud Sylvie , Belin Lisa , Gal Jocelyn
Published: April 2023

R CODE FOR MULTIPLE IMPUTATIONS
Suppl. Tables and Suppl. figure legends from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

Suppl. Table 1: Univariate analysis of different prognostic parameters in 112 patients with BUC. Suppl. Table 2. Multivariate cox regression analysis of the association of various clinicopathological features with survival in 112 patients with BUC. Suppl. figure 1-7 legends
Suppl. Figure 7 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

Effects of REDD1 and miR-22 on Taxol chemosensitivity in EJ and BIU87 cells in nude mice. (A-B) Tumor tissues isolated from indicated mice at day 35 post-transplant. (C-D) The tumor volumes were calculated at day 35 post-transplant. (E-F) Tumor cells apoptosis was tested by TUNEL assay. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.
Figure S1-S4 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Authors: Mazzaschi Giulia , Madeddu Denise , Falco Angela , Bocchialini Giovanni , Goldoni Matteo , Sogni Francesco , Armani Giovanna , Lagrasta Costanza Annamaria , Lorusso Bruno , Mangiaracina Chiara , Vilella Rocchina , Frati Caterina , Alfieri Roberta , Ampollini Luca , Veneziani Michele , Silini Enrico Maria , Ardizzoni Andrea , Urbanek Konrad , Aversa Franco , Quaini Federico , Tiseo Marcello
Published: April 2023

Clinicopathological correlations. Figure S1: PD-L1 Expression and Clinicopathologic Parameters; Figure S2: PD-L1 Expression and TILs; Figure S3: TILs and Clinicopathological Parameters; Figure S4: NSCLC Immune Microenvironments Based on PD-L1 and TILs.
table s2 from Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
Authors: Jin Xiance , Chen Yanfan , Chen Hanbin , Fei Shaoran , Chen Didi , Cai Xiaona , Liu Linger , Lin Baochai , Su Huafang , Zhao Lihao , Su Meng , Pan Huanle , Shen Lanxiao , Xie Deyao , Xie Congying
Published: April 2023

mappable miRNA was chosen for further analysis based on differentially expressed gene (DEG) analysis
Supplementary Methods from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Methods
supplemental legend from PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer
Authors: Qian David C. , Xiao Xiangjun , Byun Jinyoung , Suriawinata Arief A. , Her Stephanie C. , Amos Christopher I. , Barth Richard J.
Published: April 2023

supplemental legend
Supplementary Figures 1-20 from Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer
Authors: Méndez Olga , Peg Vicente , Salvans Cándida , Pujals Mireia , Fernández Yolanda , Abasolo Ibane , Pérez José , Matres Ana , Valeri Marta , Gregori Josep , Villarreal Laura , Schwartz Simó , Ramon y Cajal Santiago , Tabernero Josep , Cortés Javier , Arribas Joaquín , Villanueva Josep
Published: April 2023

Supplementary Figures 1-20
Figure S7 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Figure S7 Figure S7. (A) Kaplan-Meier estimates for overall survival (OS); patients were stratified according to the number of neoantigens: low rate ({less than or equal to}51; in blue) or high rate (>51; in red). (B) Heat-map showing for each patient the presence/absence of each of the type I HLA phenotypes. Presence of a type I HLA phenotype is represented with a black square, and a white square represents the absence of this phenotype. (C) Scatterplots showing the number of bioinformatically detected T-cell receptor (TCR) clones for a given number of neoantigens. The rho value represents Spearman's rank correlation. (D) Kaplan-Meier estimates for OS; patients were stratified according to the number of TCR clones: between 1 and 4 clones (in red) or less than 1 or more than
Supplementary Table S4-S7 from Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
Authors: Wang Jian , Yang Shouhui , He Peijun , Schetter Aaron J. , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Gaida Matthias M. , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Table S4: List of 201 differentially expressed genes (>1.5 fold) that were significantly associated with survival. Table S5: List of 66 inflammatory genes associated with survival. Table S6: List of 35 inflammatory genes associated with survival by Kaplan-Meier analysis. Table S7: Univariable and Multivariable Cox-Regression Analysis
Figure S2 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Figure S2 Figure S2. Flowchart of the exome analysis. The cohort is composed of 77 patients; 65 have matched tumour and normal exomes, and 12 have only a tumour exome. When matched exomes are available, single-nucleotide variants, polymorphisms, mutational signatures, ploidy, large loss of heterozygosity (LOH) and deletions, copy number alteration (CNA) clonality, neoantigens, and T-cell receptor (TCR) clonality were analysed. TRC clonality could also be estimated for patients with a tumour exome only
Figure S6 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Immunosuppressive ability of MDSC in vitro.
Figure S5 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Granulocytic and monocytic MDSC subsets.
Supplementary Figures from Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Authors: Engstrom Lars D. , Aranda Ruth , Lee Matthew , Tovar Elizabeth A. , Essenburg Curt J. , Madaj Zachary , Chiang Harrah , Briere David , Hallin Jill , Lopez-Casas Pedro P. , Baños Natalia , Menendez Camino , Hidalgo Manuel , Tassell Vanessa , Chao Richard , Chudova Darya I. , Lanman Richard B. , Olson Peter , Bazhenova Lyudmilla , Patel Sandip Pravin , Graveel Carrie , Nishino Mizuki , Shapiro Geoffrey I. , Peled Nir , Awad Mark M. , Jänne Pasi A. , Christensen James G.
Published: April 2023

Supplemental Figure 1. Glesatinib is a potent and selective MET inhibitor. Supplemental Figure 2. Waterfall plot of glesatinib activity across pre-clinical tumor models. Supplemental Figure 3. SNU-638 Criz-res line is homogeneous and harbors the F1200L and Y1230H resistance mutations on the same allele. Supplemental Figure 4. Long term treatment of a METex14 del mutant and amplified PDX model (PULM-039) leads to capmatinib and crizotinib-resistant tumors but not glesatinib-resistant tumors. Supplemental Figure 5. Molecular basis for resistance that arises from the G1163R mutation. Supplemental Figure 6. Glesatinib is active against type I MET inhibitor-resistance mutations in a spheroid growth assay.
Supplemental video S2 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Authors: Kreutzman Anna , Colom-Fernández Beatriz , Jiménez Ana Marcos , Ilander Mette , Cuesta-Mateos Carlos , Pérez-García Yaiza , Arévalo Cristina Delgado , Brück Oscar , Hakanen Henna , Saarela Jani , Ortega-Carrión Alvaro , de Rosendo Ana , Juanes-García Alba , Steegmann Juan Luis , Mustjoki Satu , Vicente-Manzanares Miguel , Muñoz-Calleja Cecilia
Published: April 2023

Recovery of HUVEC monolayer after washing out dasatinib.
Supplementary figures #1-#15 from Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer
Authors: Rosati Rayna , Polin Lisa , Ducker Charles , Li Jing , Bao Xun , Selvakumar Dakshnamurthy , Kim Seongho , Xhabija Besa , Larsen Martha , McFall Thomas , Huang Yanfang , Kidder Benjamin L. , Fribley Andrew , Saxton Janice , Kakuta Hiroki , Shaw Peter , Ratnam Manohar
Published: April 2023

Supplementary figures #1-#15
Supplementary Tables from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Authors: Zuo Wen-Jia , Jiang Yi-Zhou , Wang Yu-Jie , Xu Xiao-En , Hu Xin , Liu Guang-Yu , Wu Jiong , Di Gen-Hong , Yu Ke-Da , Shao Zhi-Ming
Published: April 2023

Supplementary Table S1. Sanger sequencing primers for all 27 exons of HER2 gene. Supplementary Table S2. Clinicopathologic characteristics of breast cancer patients enrolled in our study. Supplementary Table S3. Clinicopathologic characteristics of HER2-mutated breast cancer. Supplementary Table S4. Clinical information of patients with HER2-mutated breast cancer
Supplementary table 6 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Supplementary Data - Figure 3 from SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer
Authors: Tao Zhen , McCall Neal S. , Wiedemann Norbert , Vuagniaux Grégoire , Yuan Zhiyong , Lu Bo
Published: April 2023

Intrinsic Sensitivity to Debio 1143, ionizing radiation, and their combination. Cell viability was measured using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA) in the presence of varying concentrations of Debio 1143. Cell lines were cultured in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). 3000 cells/well were seeded into 96-well plates in triplicate. MTT assay was performed at 72 hours after treatment. At 37 {degree sign}C in humidified 5% CO2 plates were read at the absorbance of 490-nm on a microplate reader (SpectraMax M5, Phoenix, AZ). Relative cell viability of an individual sample was calculated by normalizing their absorbance to that of the corresponding control. (B) For the clonogenic assays, LLC-OVA cells were seeded into 35-mm dishes and then treated with or without Debio 1143 (10 µmol/L) and/or radiation (B) or ART (C), as indicated, in complete media for 10 days. Cell clusters containing at least 50 cells were regarded as one colony. The remaining cells were fixed with methanol (1%) and formaldehyde (1%), stained with 0.5% crystal violet, and photographed using a digital scanner. (B) At lower doses of radiation, the linear quadratic model was used to estimate survival fraction. (C) For the clonogenic assay of ablative radiation, relative colony percent formation was calculated in comparison to the plating efficiency of the 0Gy group. Statistical differences were assessed using the unpaired student t-test. P-values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001. All the experiments were repeated at least three times.
Supplementary table 2 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Supplementary Data - Figure 1 from SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer
Authors: Tao Zhen , McCall Neal S. , Wiedemann Norbert , Vuagniaux Grégoire , Yuan Zhiyong , Lu Bo
Published: April 2023

Dendritic cell infiltration is increased by combination therapy with ART and Debio 1143. Tumors harvested 12 days after ART were analyzed for CD45+CD11b+Cd11c+CD86+ dendritic cells by flow cytometry. Statistical differences were assessed using the unpaired student t-test. P-values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001.
Supplementary table 1 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Figure S4 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary Figure
Supplementary Tables S1-18 from Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer
Authors: Wang Kai-Jian , Wang Chao , Dai Li-He , Yang Jun , Huang Hai , Ma Xiao-Jing , Zhou Zhe , Yang Ze-Yu , Xu Wei-Dong , Hua Mei-Mian , Lu Xin , Zeng Shu-Xiong , Wang Hui-Qing , Zhang Zhen-Sheng , Cheng Yan-Qiong , Liu Dan , Tian Qin-Qin , Sun Ying-Hao , Xu Chuan-Liang
Published: April 2023

Supplementary Tables S1-18
Supplementary Figure 1c from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary Figure 1. Kaplan-Meier survival curves of treatment effect on TTP in patients with low (left panel) and high (right panel) baseline levels of (A) epiregulin (max chi interaction P value = 0.193), (B) VEGF-A (max chi interaction P value = 0.153), (C) HGF (max chi interaction P value = 0.157), and (D) PDGF (max chi interaction P value = 0.167). All biomarkers were dichotomized using the max chi optimized cutoff. BL=baseline; Erlot=erlotinib; HGF=hepatocyte growth factor; PDGF=platelet-derived growth factor; Pla=placebo; Sor=sorafenib; TTP=time to progression; VEGF=vascular endothelial growth factor.
Supplementary Figure 1a from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary Figure 1. Kaplan-Meier survival curves of treatment effect on TTP in patients with low (left panel) and high (right panel) baseline levels of (A) epiregulin (max chi interaction P value = 0.193), (B) VEGF-A (max chi interaction P value = 0.153), (C) HGF (max chi interaction P value = 0.157), and (D) PDGF (max chi interaction P value = 0.167). All biomarkers were dichotomized using the max chi optimized cutoff. BL=baseline; Erlot=erlotinib; HGF=hepatocyte growth factor; PDGF=platelet-derived growth factor; Pla=placebo; Sor=sorafenib; TTP=time to progression; VEGF=vascular endothelial growth factor.
Supplementary Table 1 from Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
Authors: Heske Christine M. , Davis Mindy I. , Baumgart Joshua T. , Wilson Kelli , Gormally Michael V. , Chen Lu , Zhang Xiaohu , Ceribelli Michele , Duveau Damien Y. , Guha Rajarshi , Ferrer Marc , Arnaldez Fernanda I. , Ji Jiuping , Tran Huong-Lan , Zhang Yiping , Mendoza Arnulfo , Helman Lee J. , Thomas Craig J.
Published: April 2023

Table describing details of drug screen
Supplementary Figure S2 from PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Authors: Melaiu Ombretta , Mina Marco , Chierici Marco , Boldrini Renata , Jurman Giuseppe , Romania Paolo , D'Alicandro Valerio , Benedetti Maria C. , Castellano Aurora , Liu Tao , Furlanello Cesare , Locatelli Franco , Fruci Doriana
Published: April 2023

this figure includes (A-D) Kaplan-Meier curves of OS according to the density of tumor infiltrating CD4+ T cells alone (A), or combined with PD-L1+ tumor-cell density (B), HLA-I+ tumor-cell density (C), or both (D). E-H, Kaplan-Meier curves of OS according to the density of tumor infiltrating CD8+ T cells alone (E), or combined with PD-L1+ tumor-cell density (F), HLA-I+ tumor-cell density (G), or both (H). Gray arrows indicate the increased OS between the selected groups.
Movie S4 from Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma
Authors: Davare Monika A. , Henderson Jacob J. , Agarwal Anupriya , Wagner Jacob P. , Iyer Sudarshan R. , Shah Nameeta , Woltjer Randy , Somwar Romel , Gilheeney Stephen W. , DeCarvalo Ana , Mikkelson Tom , Van Meir Erwin G. , Ladanyi Marc , Druker Brian J.
Published: April 2023

U118MG spheroid treated with 250nM lorlatinib for 72 hrs
Table S1 from Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Authors: Hsu Dennis Shin-Shian , Hwang Wei-Lun , Yuh Chiou-Hwa , Chu Chen-Hsi , Ho Yang-Hui , Chen Pon-Bo , Lin Han-Syuan , Lin Hua-Kuo , Wu Shih-Pei , Lin Chih-Yi , Hsu Wen-Hao , Lan Hsin-Yi , Wang Hsiao-Jung , Tai Shyh-Kuan , Hung Mien-Chie , Yang Muh-Hwa
Published: April 2023

S1A: S1A: Gene expression profile of OECM1-CtxR cells (1.5 folds, 1955 identities); S1B: Cetuximab resistance signature (170 identities); S1C:Gene expression profiles in FaDu-Snail cells (2.5 folds with FPKM>1, 477 genes)
RNA Seq Significant Genes from Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
Authors: Woods David M. , Ramakrishnan Rupal , Laino Andressa S. , Berglund Anders , Walton Kelly , Betts Brian C. , Weber Jeffrey S.
Published: April 2023

Significant Gene List for RNA-Seq Data
Figure S3 from Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Authors: Hsu Dennis Shin-Shian , Hwang Wei-Lun , Yuh Chiou-Hwa , Chu Chen-Hsi , Ho Yang-Hui , Chen Pon-Bo , Lin Han-Syuan , Lin Hua-Kuo , Wu Shih-Pei , Lin Chih-Yi , Hsu Wen-Hao , Lan Hsin-Yi , Wang Hsiao-Jung , Tai Shyh-Kuan , Hung Mien-Chie , Yang Muh-Hwa
Published: April 2023

Activation of NF-κB in cetuximab-resistant cells